Natchaya Vanwong

发表

CYP2D6 genotype analysis of a Thai population: platform comparison.

A. Gaedigk, C. Sukasem, A. Puangpetch, 2018, Pharmacogenomics.

Pharmacogenetics and Clinical Risk Factors for Risperidone- Related Weight Gain in Thai Autistic Spectrum Disorder Patients

C. Sukasem, A. Puangpetch, Sadeep Medhasi, 2014 .

Pharmacogenetics of Risperidone‐Induced Insulin Resistance in Children and Adolescents with Autism Spectrum Disorder

C. Sukasem, A. Puangpetch, Natchaya Vanwong, 2018, Basic & clinical pharmacology & toxicology.

Impact of CYP2D6 Polymorphism on Steady-State Plasma Levels of Risperidone and 9-Hydroxyrisperidone in Thai Children and Adolescents with Autism Spectrum Disorder.

C. Sukasem, A. Puangpetch, Sadeep Medhasi, 2017, Journal of child and adolescent psychopharmacology.

CYP2D6 polymorphisms and their influence on risperidone treatment

C. Sukasem, A. Puangpetch, Monpat Chamnanphon, 2016, Pharmacogenomics and personalized medicine.

Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan‐induced toxicity in Asian cancer patients: Meta‐analysis

C. Sukasem, M. Biswas, Natchaya Vanwong, 2021, Clinical and translational science.

Hyperuricemia in Children and Adolescents with Autism Spectrum Disorder Treated with Risperidone: The Risk Factors for Metabolic Adverse Effects

C. Sukasem, A. Puangpetch, Natchaya Vanwong, 2017, Front. Pharmacol..

Risperidone-Induced Obesity in Children and Adolescents With Autism Spectrum Disorder: Genetic and Clinical Risk Factors

C. Sukasem, A. Puangpetch, Natchaya Vanwong, 2020, Frontiers in Pharmacology.

Effects of polymorphisms in the MTHFR gene on 5-FU hematological toxicity and efficacy in Thai colorectal cancer patients

C. Sukasem, T. Reungwetwattana, A. Puangpetch, 2022, Frontiers in oncology.

Associations between UGT1A1 and SLCO1B1 polymorphisms and susceptibility to neonatal hyperbilirubinemia in Thai population

C. Sukasem, T. Jantararoungtong, A. Puangpetch, 2022, BMC Pediatrics.

Serum Prolactin level in Thai Children and Adolescents with Autistic Spectrum Disorder on Long Term Risperidone Treatments

C. Sukasem, A. Puangpetch, Natchaya Vanwong, 2014 .

Pharmacogenomic Study Reveals New Variants of Drug Metabolizing Enzyme and Transporter Genes Associated with Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Thai Autism Spectrum Disorder Patients

C. Sukasem, J. Pratoomwun, A. Puangpetch, 2016, Front. Pharmacol..

Development and Validation of Liquid Chromatography/Tandem Mass Spectrometry Analysis for Therapeutic Drug Monitoring of Risperidone and 9‐Hydroxyrisperidone in Pediatric Patients with Autism Spectrum Disorders

C. Sukasem, A. Puangpetch, Natchaya Vanwong, 2016, Journal of clinical laboratory analysis.

Association of Drug-Metabolizing Enzyme and Transporter Gene Polymorphisms and Lipid-Lowering Response to Statins in Thai Patients with Dyslipidemia

C. Sukasem, Y. Vorasettakarnkij, Sadeep Medhasi, 2022, Pharmacogenomics and personalized medicine.

Clinically relevant genetic variants of drug-metabolizing enzyme and transporter genes detected in Thai children and adolescents with autism spectrum disorder

C. Sukasem, A. Puangpetch, Sadeep Medhasi, 2016, Neuropsychiatric disease and treatment.

Neuropsychiatric Disease and Treatment Dovepress Clinically Relevant Genetic Variants of Drug- Metabolizing Enzyme and Transporter Genes Detected in Thai Children and Adolescents with Autism Spectrum Disorder Sadeep Medhasi Natchaya Vanwong Montri Chamnanphon Yaowaluck Hongkaew Penkhae Limsila

C. Sukasem, A. Puangpetch, Sadeep Medhasi, 2022 .

Pharmacogenomics and Efficacy of Risperidone Long‐Term Treatment in Thai Autistic Children and Adolescents

B. Wilffert, C. Sukasem, A. Puangpetch, 2017, Basic & clinical pharmacology & toxicology.

Pharmacogenomics in clinical practice to prevent risperidone-induced hyperprolactinemia in autism spectrum disorder.

C. Sukasem, M. Biswas, Natchaya Vanwong, 2022, Pharmacogenomics.

UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder

B. Wilffert, C. Sukasem, A. Puangpetch, 2018, The Pharmacogenomics Journal.

Impact of risperidone on leptin and insulin in children and adolescents with autistic spectrum disorders.

C. Sukasem, A. Puangpetch, M. Kroll, 2017, Clinical biochemistry.

Detection of CYP2D6 polymorphism using Luminex xTAG technology in autism spectrum disorder: CYP2D6 activity score and its association with risperidone levels.

C. Sukasem, A. Puangpetch, Natchaya Vanwong, 2016, Drug metabolism and pharmacokinetics.

Effect of 5‐HT2C receptor gene polymorphism (HTR2C−759C/T) on metabolic adverse effects in Thai psychiatric patients treated with risperidone

C. Sukasem, A. Puangpetch, Natchaya Vanwong, 2021, Pharmacoepidemiology and drug safety.

Associations of the SREBF2 Gene and INSIG2 Polymorphisms with Obesity and Dyslipidemia in Thai Psychotic Disorder Patients Treated with Risperidone

C. Sukasem, A. Puangpetch, Natchaya Vanwong, 2021, Journal of personalized medicine.

9‐Hydroxyrisperidone‐Induced Hyperprolactinaemia in Thai Children and Adolescents with Autism Spectrum Disorder

C. Sukasem, A. Puangpetch, Natchaya Vanwong, 2016, Basic & clinical pharmacology & toxicology.

Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders

C. Sukasem, A. Puangpetch, Natchaya Vanwong, 2016, Journal of clinical psychopharmacology.

Hyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone

C. Sukasem, A. Puangpetch, Natchaya Vanwong, 2015, Neuropsychiatric disease and treatment.

UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder

B. Wilffert, C. Sukasem, A. Puangpetch, 2018, The Pharmacogenomics Journal.